Infantile neuroaxonal dystrophy
Infantile Neuroaxonal Dystrophy[edit | edit source]
Infantile Neuroaxonal Dystrophy (INAD) is a rare, inherited neurodegenerative disorder that primarily affects infants and young children. It is characterized by progressive motor and cognitive decline, leading to severe disability and early death.
Etiology[edit | edit source]
INAD is caused by mutations in the PLA2G6 gene, which encodes an enzyme involved in the metabolism of phospholipids. This gene is located on chromosome 22. The disorder follows an autosomal recessive inheritance pattern, meaning that both copies of the gene in each cell have mutations.
Pathophysiology[edit | edit source]
The mutations in the PLA2G6 gene lead to the accumulation of abnormal deposits in the neurons and other cells of the nervous system. These deposits, known as spheroid bodies, disrupt normal cellular function and lead to the degeneration of nerve fibers, particularly in the brain and spinal cord.
Clinical Features[edit | edit source]
Symptoms of INAD typically begin between 6 months and 3 years of age. Early signs include:
- Developmental delay
- Loss of previously acquired motor skills
- Hypotonia (decreased muscle tone)
- Ataxia (lack of voluntary coordination of muscle movements)
- Optic atrophy leading to vision loss
As the disease progresses, affected children may develop:
Diagnosis[edit | edit source]
Diagnosis of INAD is based on clinical evaluation, genetic testing for mutations in the PLA2G6 gene, and neuroimaging studies such as MRI that may show characteristic changes in the brain. A nerve biopsy may reveal the presence of spheroid bodies.
Management[edit | edit source]
There is currently no cure for INAD, and treatment is primarily supportive. Management focuses on alleviating symptoms and improving quality of life. This may include:
- Physical therapy to maintain mobility
- Medications to control seizures
- Nutritional support
Prognosis[edit | edit source]
The prognosis for children with INAD is poor. The disease progresses rapidly, and most affected individuals do not survive beyond their first decade of life.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD